FDA Promises Imminent Guidance On Interchangeable Biosimilar Exclusivity
Planned List For 2025 Also Includes Numerous Other Generics Guidances
The FDA’s CDER has set out a 2025 guidance agenda that promises long-awaited guidance on first interchangeable biosimilar exclusivity, as well as a host of other documents relevant to generic drug development and registration.
